Financial Statements

Aptevo Therapeutics Inc. (APVO)

$4.69

+0.63 (+15.52%)

Cash Flow Statement

All numbers are in thousands
Year XLSX
2023
XLSX
2022
XLSX
2021
XLSX
2020
XLSX
2019
Operating Cash Flow -11,730-21,022-21,679-29,318-42,383
Net Income -18,6508,027-28,457-17,750-40,448
Depreciation & Amortization 5679011,1441,4062,235
Deferred income taxes -518-4-12,234-4,250
Stock-based compensation 2,1931,8021,6431,2551,598
Change in working capital 2,9112,144-2,655-2,406-2,191
Other non-cash items 1,767-33,8966,642411673
Investing Cash Flow --29-71328,0324,097
Investments in PPE --29-713-88-153
Acquisitions ---28,1204,250
Financing Cash Flow 5,998-2,61626,16123,87420,149
Debt repayment -3,467-12,267-10,550-22,104-137
Dividends payments --4-10,233-21,247-58
Common Stock Repurchased --410,233-11-58
Common Stock Issuance 9,4756,93410,23321,25820,344
Other Financing Activites -102,72526,47845,97858
Accounts receivables 2,5001,164-1,295-2,369-1,802
Accounts payables 518-394-1,915-702-2,697
Inventory --1,1641,295-1,054-4,354
Other working capital -1072,538-7401,7196,662
Cash at beginning of period 22,63546,30342,53419,94638,083
Cash at end of period 16,90422,63646,30342,53419,946
Capital Expenditure --29-713-88-153
Net cash flow / Change in cash -5,731-23,6673,76922,588-18,137
Free Cash Flow -11,730-21,051-22,392-29,406-42,536

Aptevo Therapeutics Inc. income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes Aptevo Therapeutics Inc. FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.